Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
54
STRO Quote, Financials, Valuation and Earnings
Last price:
$12.31
Seasonality move
:
-14.43%
Day range:
$11.88 - $13.30
52-week range:
$5.23 - $21.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.13x
P/B ratio:
1.64x
Volume:
204.7K
Avg. volume:
120.4K
1-year change:
-37.28%
Market cap:
$104.2M
Revenue:
$62M
EPS (TTM):
-$17.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
|
$7.6M | -$4.43 | -43.68% | -49.53% | $21.00 |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$7.4M | -$1.37 | 1955.07% | -33.3% | $82.93 |
|
DARE
Daré Bioscience, Inc.
|
$1.6M | -$0.36 | 2911.81% | -13.48% | $10.75 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$70.8M | -$0.54 | 734.42% | -46.85% | $39.31 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
|
$12.23 | $21.00 | $104.2M | -- | $0.00 | 0% | 3.13x |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$53.25 | $82.93 | $5.1B | -- | $0.00 | 0% | 3,231.44x |
|
DARE
Daré Bioscience, Inc.
|
$1.98 | $10.75 | $28.3M | 95.38x | $0.00 | 0% | 399.70x |
|
GTBP
GT Biopharma, Inc.
|
$0.68 | $8.00 | $7.2M | -- | $0.00 | 0% | 59.35x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$21.00 | $39.31 | $1.8B | -- | $0.00 | 0% | 16.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
|
162.21% | 2.031 | 307.89% | 2.39x |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
4.38% | 0.547 | 1.25% | 14.74x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.066 | 27.91% | 1.09x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.132 | 4.06% | 1.98x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
74.95% | -0.941 | 25.84% | 4.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
|
$7.8M | -$38.9M | -101.26% | -10195.04% | -401.33% | -$38.4M |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
-$869K | -$142.6M | -35.8% | -37.41% | -99710.49% | -$111.6M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$43.8M | -$57.4M | -61.68% | -136.36% | -125.19% | -$70.7M |
Sutro Biopharma, Inc. vs. Competitors
-
Which has Higher Returns STRO or CRNX?
Crinetics Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -90972.73%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma, Inc.80.4% -$6.70 $140.3M CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B -
What do Analysts Say About STRO or CRNX?
Sutro Biopharma, Inc. has a consensus price target of $21.00, signalling upside risk potential of 71.71%. On the other hand Crinetics Pharmaceuticals, Inc. has an analysts' consensus of $82.93 which suggests that it could grow by 55.87%. Given that Sutro Biopharma, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma, Inc.4 4 0 CRNXCrinetics Pharmaceuticals, Inc.11 2 0 -
Is STRO or CRNX More Risky?
Sutro Biopharma, Inc. has a beta of 1.526, which suggesting that the stock is 52.558% more volatile than S&P 500. In comparison Crinetics Pharmaceuticals, Inc. has a beta of 0.196, suggesting its less volatile than the S&P 500 by 80.394%.
-
Which is a Better Dividend Stock STRO or CRNX?
Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Crinetics Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or CRNX?
Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Crinetics Pharmaceuticals, Inc. quarterly revenues of $143K. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Crinetics Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 3.13x versus 3,231.44x for Crinetics Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma, Inc.3.13x -- $9.7M -$56.9M CRNXCrinetics Pharmaceuticals, Inc.3,231.44x -- $143K -$130.1M
-
Which has Higher Returns STRO or DARE?
Daré Bioscience, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -154904.35%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma, Inc.80.4% -$6.70 $140.3M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About STRO or DARE?
Sutro Biopharma, Inc. has a consensus price target of $21.00, signalling upside risk potential of 71.71%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 442.93%. Given that Daré Bioscience, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Sutro Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma, Inc.4 4 0 DAREDaré Bioscience, Inc.3 0 0 -
Is STRO or DARE More Risky?
Sutro Biopharma, Inc. has a beta of 1.526, which suggesting that the stock is 52.558% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.
-
Which is a Better Dividend Stock STRO or DARE?
Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or DARE?
Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 3.13x versus 399.70x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma, Inc.3.13x -- $9.7M -$56.9M DAREDaré Bioscience, Inc.399.70x 95.38x $2.3K -$3.6M
-
Which has Higher Returns STRO or GTBP?
GT Biopharma, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of --. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma, Inc.80.4% -$6.70 $140.3M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About STRO or GTBP?
Sutro Biopharma, Inc. has a consensus price target of $21.00, signalling upside risk potential of 71.71%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1081.68%. Given that GT Biopharma, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Sutro Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma, Inc.4 4 0 GTBPGT Biopharma, Inc.1 0 0 -
Is STRO or GTBP More Risky?
Sutro Biopharma, Inc. has a beta of 1.526, which suggesting that the stock is 52.558% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.172, suggesting its more volatile than the S&P 500 by 17.17%.
-
Which is a Better Dividend Stock STRO or GTBP?
Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or GTBP?
Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 3.13x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma, Inc.3.13x -- $9.7M -$56.9M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns STRO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -255.85%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma, Inc.80.4% -$6.70 $140.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About STRO or NBY?
Sutro Biopharma, Inc. has a consensus price target of $21.00, signalling upside risk potential of 71.71%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Sutro Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma, Inc.4 4 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is STRO or NBY More Risky?
Sutro Biopharma, Inc. has a beta of 1.526, which suggesting that the stock is 52.558% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock STRO or NBY?
Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or NBY?
Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 3.13x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma, Inc.3.13x -- $9.7M -$56.9M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns STRO or SNDX?
Syndax Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -132.36%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma, Inc.80.4% -$6.70 $140.3M SNDXSyndax Pharmaceuticals, Inc.95.42% -$0.70 $460.9M -
What do Analysts Say About STRO or SNDX?
Sutro Biopharma, Inc. has a consensus price target of $21.00, signalling upside risk potential of 71.71%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 87.18%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Sutro Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma, Inc.4 4 0 SNDXSyndax Pharmaceuticals, Inc.12 0 0 -
Is STRO or SNDX More Risky?
Sutro Biopharma, Inc. has a beta of 1.526, which suggesting that the stock is 52.558% more volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.46%.
-
Which is a Better Dividend Stock STRO or SNDX?
Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or SNDX?
Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are smaller than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 3.13x versus 16.23x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma, Inc.3.13x -- $9.7M -$56.9M SNDXSyndax Pharmaceuticals, Inc.16.23x -- $45.9M -$60.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
